Nasdaq Stro News Today

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...

Sutro Biopharma (NASDAQ:STRO – Free Report) had its price target cut by HC Wainwright from $16.00 to $12.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Sutro Biopharma’s Q1 2024 earnings at ($0.95) EPS, Q2 2024 earnings […]

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among […]

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average […]

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) insider Nicki Vasquez sold 12,185 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $5.00, for a total value of $60,925.00. Following the completion of the transaction, the insider now directly owns 12,803 shares of […]

Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research report issued to clients and investors on Friday, RTT News reports. They presently have a $12.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 243.84% from the stock’s current […]

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price […]

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have received a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price […]

Sutro Biopharma, Inc. (NASDAQ:STRO – Free Report) – Equities research analysts at HC Wainwright raised their FY2023 EPS estimates for Sutro Biopharma in a report issued on Tuesday, November 14th. HC Wainwright analyst A. Fein now expects that the company will earn ($2.94) per share for the year, up from their prior forecast of ($2.96). […]